Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs

Journal of Pain

Volumn 11, Issue 4, 2010, Pages 360-368

  Dworkin, Robert H ^a   Malone, Daniel C ^b   Panarites, Christopher J ^c   Armstrong, Edward P ^b   Pham, Sissi V ^d  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c NeurogesX Inc   (United States)

^d Sissi Pham Consulting Inc   (United States)

Author keywords

diabetic peripheral neuropathy; health care costs; neuropathic pain; Postherpetic neuralgia

Indexed keywords

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DRUG COST; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT CARE; PERIPHERAL NEUROPATHY; PHARMACY; POSTHERPETIC NEURALGIA; PROFESSIONAL PRACTICE; SCORING SYSTEM;

AGED; ANALGESICS; COHORT STUDIES; COMORBIDITY; DATABASES AS TOPIC; DIABETES MELLITUS; DIABETIC NEUROPATHIES; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HERPES ZOSTER; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RETROSPECTIVE STUDIES;

EID: 77949916692     PISSN: 15265900     EISSN: 15288447     Source Type: Journal    
DOI: 10.1016/j.jpain.2009.08.005     Document Type: Article

References (41)

1. Attal N., Cruccu G., Haanpää M., Hansson P., Jensen T.S., Nurmikko T., Sampaio C., Sindrup S., and Wiffen P. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13 (2006) 1153-1169
2. Barrett A.M., Lucero M.A., Le T., Robinson R.L., Dworkin R.H., and Chappell A.S. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med 8 suppl 2 (2007) S50-S62
3. Berger A., Dukes E.M., and Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 5 (2004) 143-149
4. Bouhassira D., Lantéri-Minet M., Attal, Laurent B., and Touboul C. Prevalence of chronic pain with neuropathic characteristics ion the general population. Pain 136 (2008) 380-387
5. Boulton A.J.M., Malik R.A., Arezzo J.C., and Sosenko J.M. Diabetic somatic neuropathies. Diabetes Care 27 (2004) 1458-1486
6. Boulton A.J.M., Vinik A.I., Arezzo J.C., Bril V., Feldman E.L., Freeman R., Malik R.A., Maser R.E., Sosenko J.M., and Ziegeler D. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 28 (2005) 956-962
7. Brisson M., Edmunds W.J., and Gay N.J. Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 70 suppl 1 (2003) S31-S37
8. Cepeda M.S., and Farrar J.T. Economic evaluation of oral treatments for neuropathic pain. J Pain 7 (2006) 119-128
9. Charlson M.E., Pompei P., Ales K.L., and McKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40 (1987) 373-383
10. Cruccu G., Aziz T.Z., Garcia-Larrea L., Hansson P., Jensen T.S., Lefaucheur J.P., Simpson B.A., and Taylor R.S. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 14 (2007) 952-970
11. Dworkin R.H., Gnann Jr. J.W., Oaklander A.L., Raja S., Schmader K.E., and Whitley R.J. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 9 suppl 1 (2008) S37-S44
12. Dworkin R.H., Johnson R.W., Breuer J., Gnann J.W., Levin M.J., Backonja M., Betts R.F., Gershon A.A., Haanpää M.L., McKendrick M.W., Nurmikko T.J., Oaklander A.L., Oxman M.N., Pavan-Langston D., Petersen K.L., Rowbotham M.C., Schmader K.E., Stacey B.R., Tyring S.K., van Wijck A.J.M., Wallace M.S., Wassilew S.W., and Whitley R.J. Recommendations for the management of herpes zoster. Clin Infect Dis 44 Suppl 1 (2007) S1-S26
13. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S.C., Stacey B.R., Treede R.-D., Turk D.C., and Wallace M.S. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132 (2007) 237-251
14. Dworkin R.H., Panarites C., and Chen C. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on healthcare costs. J Pain 10 suppl 1 (2009) S17
15. Dworkin R.H., White R., O'Connor A.B., Baser O., and Hawkins K. Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 55 (2007) 1168-1175
16. Dworkin R.H., White R., O'Connor A.B., and Hawkins K. Healthcare expenditure burden of persisting herpes zoster pain. Pain Med 9 (2008) 348-353
17. Garnett G.P., and Ferguson N.M. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol 6 (1996) 151-161
18. Gauthier A., Breuer J., Carrington D., Martin M., and Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 137 (2009) 38-47
19. Gordois A., Scuffham P., Shearer A., Oglesby A., and Tobian J.A. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26 (2003) 1790-1795
20. Gore M., Brandenburg N.A., Hoffman D.L., Tai K.S., and Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 7 (2006) 892-900
21. Grant D.M., Mauskopf J.A., Bell L., and Austin R. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: A cost-consequence model. Pharmacotherapy 17 (1997) 333-341
22. Hornburger J., and Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 145 (2006) 317-325
23. Insinga R.P., Itzler R.F., and Pellissier J.M. Acute/subacute herpes zoster: Healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 25 (2007) 155-169
24. Jensen M.P., Chodroff M.J., and Dworkin R.H. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology 68 (2007) 1178-1182
25. Lachaine J., Gordon A., Choinière M., Collet J., Dion D., and Tarride J. Painful neuropathic disorders: An analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manage 12 (2007) 31-37
26. McDermott A.M., Toelle T.R., Rowbotham D.J., Schaefer C.P., and Dukes E.M. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 10 (2006) 127-135
27. Meyer-Rosberg K., Kvarnstrom A., Kinnman E., Gordh T., Nordfors L.O., and Kristofferson A. Peripheral neuropathic pain: A multidimensional burden for patients. Eur J Pain 5 (2001) 379-389
28. Morbidity and Mortality Weekly Report. State-specific incidence of diabetes among adults: Participating states, 1995-1997 and 2005-2007. MMWR 57 (2008) 1169-1173
29. Moulin D.E., Clark A.J., Gilron I., Ware M.A., Watson C.P.N., Sessle B.J., Coderre T., Morley-Foster P.K., Stinson J., Boulanger A., Peng P., Finley G.A., Taenzer P., Squire P., Dion D., Cholkan A., Gilani A., Gordon A., Henry J., Jovey R., Lynch M., Mailis-Gagnon A., Panju A., Rollman G.B., and Velly A. Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage 12 (2007) 13-21
30. O'Connor A.B. Neuropathic pain: A review of the quality-of-life impact, costs, and cost effectiveness of therapy. Pharmacoeconomics 27 (2009) 1-18
31. O'Connor A.B., Noyes K., and Holloway R.G. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc 55 (2007) 1176-1184
32. O'Connor A.B., Noyes K., and Holloway R.G. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics 26 (2008) 1045-1064
33. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., Arbeit R.D., Simberkoff M.S., Gershon A.A., Davis L.E., Weinberg A., Boardman K.D., Williams H.M., Zhang J.H., Peduzzi P.N., Beisel C.E., Morrison V.A., Guatelli J.C., Brooks P.A., Kauffman C.A., Pachucki C.T., Neuzil K.M., Betts R.F., Wright P.F., Griffin M.R., Brunell P., Soto N.E., Marques A.R., Keay S.K., Goodman R.P., Cotton D.J., Gnann Jr. J.W., Loutit J., Holodniy M., Keitel W.A., Crawford G.E., Yeh S.-S., Lobo Z., Toney J.F., Greenberg R.N., Keller P.M., Harbecke R., Hayward A.R., Irwin M.R., Kyriakides T.C., Chan C.Y., Chan I.S., Wang W.W., Annunziato P.W., Silber J.L., and Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
34. Russell M.L., Schopflocher D.P., Svenson L., and Virani S.N. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 135 (2007) 908-913
35. Schmader K.E. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 18 (2002) 350-354
36. Schmader K., Gnann Jr. J.W., and Watson C.P. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 197 (2008) S207-S215 2008
37. Schuette M.C., and Hethcote H.W. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 61 (1999) 1031-1064
38. Stein A.N., Britt H., Harrison C., Conway E.L., Cunningham A., and MacIntyre C.R. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine 27 (2009) 520-529
39. Thomas S.L., and Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 4 (2004) 26-33
40. Treede R.-D., Jensen T.S., Campbell J.N., Cruccu G., Dostrovsky J.O., Griffin J.W., Hansson P., Hughes R., Nurmikko T., and Serra J. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 70 (2008) 1630-1635
41. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., and Seward J.F. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5 (2005) 68